Seattle life sciences industry has strength in numbers despite uncertainty

Juno Therapeutics quickly became an industry favorite when it spun out of the Fred Hutchinson Cancer Research Center in 2013.

The cancer therapy company raised $120 million in its first round of funding, making it one of the largest startups in biotech, thanks largely to its liso-cel therapy for non-Hodgkin lymphoma. By 2014, the company had gone public and by 2016, it had 450 employees, adding 150 in the span of six months.

But the scene is rapidly changing for Seattle’s life sciences industry.